Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Ito, T. Sano, J. Mizusawa, D. Takahari, H. Katayama, H. Katai, Y. Kawashima, T. Kinoshita, M. Terashima, A. Nashimoto, M. Nakamori, H. Onaya, M. Sasako (2017)
A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002Gastric Cancer, 20
Japanese Association (2011)
Japanese classification of gastric carcinoma: 3rd English editionGastric Cancer, 14
( Tsuburaya A , Mizusawa J , Tanaka Y , Fukushima N , Nashimoto A , Sasako M . Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.24668391)
Tsuburaya A , Mizusawa J , Tanaka Y , Fukushima N , Nashimoto A , Sasako M . Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.24668391Tsuburaya A , Mizusawa J , Tanaka Y , Fukushima N , Nashimoto A , Sasako M . Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.24668391, Tsuburaya A , Mizusawa J , Tanaka Y , Fukushima N , Nashimoto A , Sasako M . Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.24668391
( Dindo D , Demartines N , Clavien PA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.15273542)
Dindo D , Demartines N , Clavien PA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.15273542Dindo D , Demartines N , Clavien PA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.15273542, Dindo D , Demartines N , Clavien PA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.15273542
Kazuhiro Yoshida, Y. Kodera, M. Kochi, W. Ichikawa, Y. Kakeji, T. Sano, N. Nagao, Masazumi Takahashi, A. Takagane, Takuya Watanabe, M. Kaji, H. Okitsu, T. Nomura, T. Matsui, T. Yoshikawa, J. Matsuyama, M. Yamada, S. Ito, M. Takeuchi, M. Fujii (2019)
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled TrialJournal of Clinical Oncology, 37
T. Suzuki, K. Tanabe, J. Taomoto, H. Yamamoto, N. Tokumoto, K. Yoshida, H. Ohdan (2010)
Preliminary trial of adjuvant surgery for advanced gastric cancer.Oncology letters, 1 4
: a retrospective multicenter cohort study ( KSCC 1302 )
( Morgagni P , Solaini L , Framarini M , et al. Conversion surgery for gastric cancer: a cohort study from a western center. Int J Surg. 2018;12(53):360–5.)
Morgagni P , Solaini L , Framarini M , et al. Conversion surgery for gastric cancer: a cohort study from a western center. Int J Surg. 2018;12(53):360–5.Morgagni P , Solaini L , Framarini M , et al. Conversion surgery for gastric cancer: a cohort study from a western center. Int J Surg. 2018;12(53):360–5., Morgagni P , Solaini L , Framarini M , et al. Conversion surgery for gastric cancer: a cohort study from a western center. Int J Surg. 2018;12(53):360–5.
( Sasako M , Sano T , Yamamoto S , et al. D2 lymphadenectomy alone or with para‐aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.18669424)
Sasako M , Sano T , Yamamoto S , et al. D2 lymphadenectomy alone or with para‐aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.18669424Sasako M , Sano T , Yamamoto S , et al. D2 lymphadenectomy alone or with para‐aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.18669424, Sasako M , Sano T , Yamamoto S , et al. D2 lymphadenectomy alone or with para‐aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.18669424
( Yamaguchi K , Yoshida K , Tanahashi T , et al. The long‐term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2017;21(2):315–23.28616743)
Yamaguchi K , Yoshida K , Tanahashi T , et al. The long‐term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2017;21(2):315–23.28616743Yamaguchi K , Yoshida K , Tanahashi T , et al. The long‐term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2017;21(2):315–23.28616743, Yamaguchi K , Yoshida K , Tanahashi T , et al. The long‐term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2017;21(2):315–23.28616743
( Kodera Y , Fujitani K , Fukushima N , et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2013;17(2):206–12.)
Kodera Y , Fujitani K , Fukushima N , et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2013;17(2):206–12.Kodera Y , Fujitani K , Fukushima N , et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2013;17(2):206–12., Kodera Y , Fujitani K , Fukushima N , et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2013;17(2):206–12.
Y. Bang, Young-Woo Kim, Han-Kwang Yang, H. Chung, Young-Kyu Park, K. Lee, Keunsung Lee, Yong Kim, S. Noh, J. Cho, Y. Mok, Yeul-Hong Kim, J. Ji, T. Yeh, P. Button, F. Sirzén, S. Noh (2012)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialThe Lancet, 379
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
( Mandard AM , Dalibard F , Mandard JC , et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations. Cancer. 1994;73(11):2680–6.8194005)
Mandard AM , Dalibard F , Mandard JC , et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations. Cancer. 1994;73(11):2680–6.8194005Mandard AM , Dalibard F , Mandard JC , et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations. Cancer. 1994;73(11):2680–6.8194005, Mandard AM , Dalibard F , Mandard JC , et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations. Cancer. 1994;73(11):2680–6.8194005
W. Koizumi, N. Nakayama, S. Tanabe, Tohru Sasaki, K. Higuchi, K. Nishimura, S. Takagi, M. Azuma, T. Ae, K. Ishido, K. Nakatani, A. Naruke, C. Katada (2012)
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)Cancer Chemotherapy and Pharmacology, 69
Japanese Association (2011)
Japanese gastric cancer treatment guidelines 2010 (ver. 3)Gastric Cancer, 14
( Ito S , Sano T , Mizusawa J , et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S‐1 followed by gastrectomy with D2 plus para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2016;20(2):322–31.27299887)
Ito S , Sano T , Mizusawa J , et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S‐1 followed by gastrectomy with D2 plus para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2016;20(2):322–31.27299887Ito S , Sano T , Mizusawa J , et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S‐1 followed by gastrectomy with D2 plus para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2016;20(2):322–31.27299887, Ito S , Sano T , Mizusawa J , et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S‐1 followed by gastrectomy with D2 plus para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2016;20(2):322–31.27299887
M. Terashima (2016)
Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru?Gastric Cancer, 19
( Han DS , Suh YS , Kong SH , et al. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol. 2012;107(5):511–6.23090791)
Han DS , Suh YS , Kong SH , et al. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol. 2012;107(5):511–6.23090791Han DS , Suh YS , Kong SH , et al. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol. 2012;107(5):511–6.23090791, Han DS , Suh YS , Kong SH , et al. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol. 2012;107(5):511–6.23090791
(2019)
Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence‐based, multi‐disciplinary approach, 19
( Solaini L , Ministrini S , Bencivenga M , et al. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019;22(6):1285–93.31065878)
Solaini L , Ministrini S , Bencivenga M , et al. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019;22(6):1285–93.31065878Solaini L , Ministrini S , Bencivenga M , et al. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019;22(6):1285–93.31065878, Solaini L , Ministrini S , Bencivenga M , et al. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019;22(6):1285–93.31065878
Y. Yamada, K. Higuchi, K. Nishikawa, M. Gotoh, N. Fuse, N. Sugimoto, T. Nishina, K. Amagai, K. Chin, Y. Niwa, A. Tsuji, H. Imamura, M. Tsuda, H. Yasui, H. Fujii, K. Yamaguchi, H. Yasui, S. Hironaka, K. Shimada, H. Miwa, C. Hamada, I. Hyodo (2015)
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 26 1
W. Koizumi, H. Narahara, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, W. Takiyama, Y. Toh, T. Nagaie, S. Takagi, Y. Yamamura, K. Yanaoka, H. Orita, M. Takeuchi (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.The Lancet. Oncology, 9 3
( Kang YK , Kang WK , Shin DB , et al. Capecitabine/cisplatin versus 5‐fluorouracil/cisplatin as first‐line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.19153121)
Kang YK , Kang WK , Shin DB , et al. Capecitabine/cisplatin versus 5‐fluorouracil/cisplatin as first‐line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.19153121Kang YK , Kang WK , Shin DB , et al. Capecitabine/cisplatin versus 5‐fluorouracil/cisplatin as first‐line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.19153121, Kang YK , Kang WK , Shin DB , et al. Capecitabine/cisplatin versus 5‐fluorouracil/cisplatin as first‐line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.19153121
( Eisenhauer EA , Therasse P , Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008;29(45):228–47.)
Eisenhauer EA , Therasse P , Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008;29(45):228–47.Eisenhauer EA , Therasse P , Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008;29(45):228–47., Eisenhauer EA , Therasse P , Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008;29(45):228–47.
P. Morgagni, L. Solaini, M. Framarini, G. Vittimberga, A. Gardini, D. Tringali, M. Valgiusti, M. Monti, G. Ercolani (2018)
Conversion surgery for gastric cancer: A cohort study from a western center.International journal of surgery, 53
( GLOBOCAN2018 . CANCER FACT SHEETS. [updated 2018; cited 18 Oct 2020]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900‐world‐fact‐sheets.pdf )
GLOBOCAN2018 . CANCER FACT SHEETS. [updated 2018; cited 18 Oct 2020]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900‐world‐fact‐sheets.pdfGLOBOCAN2018 . CANCER FACT SHEETS. [updated 2018; cited 18 Oct 2020]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900‐world‐fact‐sheets.pdf , GLOBOCAN2018 . CANCER FACT SHEETS. [updated 2018; cited 18 Oct 2020]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900‐world‐fact‐sheets.pdf
E. Oki, S. Tokunaga, Y. Emi, T. Kusumoto, Manabu Yamamoto, K. Fukuzawa, I. Takahashi, S. Ishigami, A. Tsuji, H. Higashi, Toshihiko Nakamura, H. Saeki, K. Shirabe, Y. Kakeji, K. Sakai, H. Baba, T. Nishimaki, S. Natsugoe, Y. Maehara, Kyushu Cancer (2016)
Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302)Gastric Cancer, 19
Y. Kodera, D. Kobayashi, C. Tanaka, M. Fujiwara (2015)
Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer?Surgery Today, 45
(2019)
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary ApproachJournal of Gastric Cancer, 19
( J Gastric Cancer. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence‐based, multi‐disciplinary approach. 2019;19(1):1–48.30944757)
J Gastric Cancer. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence‐based, multi‐disciplinary approach. 2019;19(1):1–48.30944757J Gastric Cancer. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence‐based, multi‐disciplinary approach. 2019;19(1):1–48.30944757, J Gastric Cancer. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence‐based, multi‐disciplinary approach. 2019;19(1):1–48.30944757
Y. Kodera, K. Fujitani, N. Fukushima, S. Ito, K. Muro, N. Ohashi, T. Yoshikawa, D. Kobayashi, C. Tanaka, M. Fujiwara (2014)
Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelinesGastric Cancer, 17
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE)
M. Sasako, T. Sano, Seiichiro Yamamoto, Y. Kurokawa, A. Nashimoto, A. Kurita, M. Hiratsuka, T. Tsujinaka, T. Kinoshitá, K. Arai, Y. Yamamura, K. Okajima (2008)
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.The New England journal of medicine, 359 5
Dong-Seok Han, Y. Suh, S. Kong, H. Lee, S. Im, Y. Bang, W. Kim, Han-Kwang Yang (2013)
Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastasesJournal of Surgical Oncology, 107
LGM Sobin, C Wittekind (2009)
TNM classification of malignant tumours
Y. Yamada, N. Boku, J. Mizusawa, S. Iwasa, S. Kadowaki, N. Nakayama, M. Azuma, Takeshi Sakamoto, K. Shitara, T. Tamura, K. Chin, H. Hata, M. Nakamori, H. Hara, H. Yasui, H. Katayama, H. Fukuda, T. Yoshikawa, M. Sasako, M. Terashima (2019)
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.The lancet. Gastroenterology & hepatology, 4 7
M. Terashima, Kazuhiro Yoshida, S. Rha, J. Bae, Guoxin Li, H. Katai, M. Watanabe, Y. Seto, Han-Kwang Yang, J. Ji, H. Baba, Y. Kitagawa, S. Morita, M. Nishiyama (2018)
International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).Journal of Clinical Oncology, 36
K. Fujitani, Han-Kwang Yang, J. Mizusawa, Young-Woo Kim, M. Terashima, Sang-Uk Han, Y. Iwasaki, W. Hyung, A. Takagane, D. Park, T. Yoshikawa, S. Hahn, Kenichi Nakamura, C. Park, Y. Kurokawa, Y. Bang, B. Park, M. Sasako, T. Tsujinaka (2016)
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.The Lancet. Oncology, 17 3
( Yamada Y , Boku N , Mizusawa J , et al. Docetaxel plus cisplatin and S‐1 versus cisplatin and S‐1 in patients with advanced gastric cancer (JCOG1013): an open‐label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–10.31101534)
Yamada Y , Boku N , Mizusawa J , et al. Docetaxel plus cisplatin and S‐1 versus cisplatin and S‐1 in patients with advanced gastric cancer (JCOG1013): an open‐label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–10.31101534Yamada Y , Boku N , Mizusawa J , et al. Docetaxel plus cisplatin and S‐1 versus cisplatin and S‐1 in patients with advanced gastric cancer (JCOG1013): an open‐label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–10.31101534, Yamada Y , Boku N , Mizusawa J , et al. Docetaxel plus cisplatin and S‐1 versus cisplatin and S‐1 in patients with advanced gastric cancer (JCOG1013): an open‐label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–10.31101534
Kazuhiro Yoshida, K. Yamaguchi, N. Okumura, S. Osada, Takao Takahashi, Yoshihiro Tanaka, K. Tanabe, Takahisa Suzuki (2011)
The Roles of Surgical Oncologists in the New Era – Minimally Invasive Surgery for Early Gastric Cancer and Adjuvant Surgery for Metastatic Gastric CancerPathobiology, 78
( Amin MB , Edge S , Greene F , et al. AJCC cancer staging manual, 8th edn. New York: Springer; 2017.)
Amin MB , Edge S , Greene F , et al. AJCC cancer staging manual, 8th edn. New York: Springer; 2017.Amin MB , Edge S , Greene F , et al. AJCC cancer staging manual, 8th edn. New York: Springer; 2017., Amin MB , Edge S , Greene F , et al. AJCC cancer staging manual, 8th edn. New York: Springer; 2017.
( Terashima M . Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? Gastric Cancer. 2016;7(19):685–6.)
Terashima M . Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? Gastric Cancer. 2016;7(19):685–6.Terashima M . Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? Gastric Cancer. 2016;7(19):685–6., Terashima M . Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? Gastric Cancer. 2016;7(19):685–6.
J. Cooper (1997)
Ajcc Cancer Staging Manual
Ch. Wittekind, M. Gospodarowicz, L. Sobin (2009)
TNM Classification of Malignant Tumours, 7th Edition
( Fujitani K , Yang HK , Mizusawa J , et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non‐curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.26822397)
Fujitani K , Yang HK , Mizusawa J , et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non‐curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.26822397Fujitani K , Yang HK , Mizusawa J , et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non‐curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.26822397, Fujitani K , Yang HK , Mizusawa J , et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non‐curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.26822397
( Koizumi W , Nakayama N , Tanabe S , et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S‐1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 2011;69(2):407–13.21796483)
Koizumi W , Nakayama N , Tanabe S , et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S‐1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 2011;69(2):407–13.21796483Koizumi W , Nakayama N , Tanabe S , et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S‐1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 2011;69(2):407–13.21796483, Koizumi W , Nakayama N , Tanabe S , et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S‐1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 2011;69(2):407–13.21796483
( Tomasello G , Petrelli F , Ghidini M , et al. Tumor regression grade and survival after neoadjuvant treatment in gastro‐esophageal cancer: a meta‐analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607–16.28347525)
Tomasello G , Petrelli F , Ghidini M , et al. Tumor regression grade and survival after neoadjuvant treatment in gastro‐esophageal cancer: a meta‐analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607–16.28347525Tomasello G , Petrelli F , Ghidini M , et al. Tumor regression grade and survival after neoadjuvant treatment in gastro‐esophageal cancer: a meta‐analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607–16.28347525, Tomasello G , Petrelli F , Ghidini M , et al. Tumor regression grade and survival after neoadjuvant treatment in gastro‐esophageal cancer: a meta‐analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607–16.28347525
L. Solaini, S. Ministrini, M. Bencivenga, A. D’Ignazio, E. Marino, C. Cipollari, B. Molteni, G. Mura, D. Marrelli, L. Graziosi, F. Roviello, G. Manzoni, G. Tiberio, P. Morgagni (2019)
Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort studyGastric Cancer
W. Koizumi, Yeul-Hong Kim, M. Fujii, Hoon‐Kyo Kim, H. Imamura, K. Lee, T. Hara, H. Chung, T. Satoh, J. Cho, H. Hosaka, A. Tsuji, A. Takagane, M. Inokuchi, K. Tanabe, T. Okuno, M. Ogura, Kazuhiro Yoshida, M. Takeuchi, T. Nakajima (2013)
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)Journal of Cancer Research and Clinical Oncology, 140
T. Kinoshitá, T. Kinoshita, A. Saiura, M. Esaki, H. Sakamoto, T. Yamanaka (2015)
Multicentre analysis of long‐term outcome after surgical resection for gastric cancer liver metastasesBritish Journal of Surgery, 102
( Oki E , Tokunaga S , Emi Y , et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2015;19(3):968–76.26260876)
Oki E , Tokunaga S , Emi Y , et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2015;19(3):968–76.26260876Oki E , Tokunaga S , Emi Y , et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2015;19(3):968–76.26260876, Oki E , Tokunaga S , Emi Y , et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2015;19(3):968–76.26260876
A. Mandard, F. Dalibard, J. Mandard, J. Marnay, M. Henry-Amar, J. Petiot, A. Roussel, J. Jacob, P. Ségol, G. Samama, J. Ollivier, S. Bonvalot, M. Gignoux (1994)
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlationsCancer, 73
D. Dindo, N. Demartines, P. Clavien (2004)
Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a SurveyAnnals of Surgery, 240
胃癌研究会 (1995)
Japanese classification of gastric carcinoma
(2016)
with extensive lymph node metastasis : JCOG 1002
( Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113‐23.21573742)
Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113‐23.21573742Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113‐23.21573742, Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113‐23.21573742
G. Tomasello, F. Petrelli, M. Ghidini, E. Pezzica, R. Passalacqua, F. Steccanella, L. Turati, G. Sgroi, S. Barni (2017)
Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 43 9
( Masuishi T , Kadowaki S , Kondo M , et al. FOLFOX as first‐line therapy for gastric cancer with severe peritoneal metastasis. Anticancer Res. 2017;37(12):7037–42.29187492)
Masuishi T , Kadowaki S , Kondo M , et al. FOLFOX as first‐line therapy for gastric cancer with severe peritoneal metastasis. Anticancer Res. 2017;37(12):7037–42.29187492Masuishi T , Kadowaki S , Kondo M , et al. FOLFOX as first‐line therapy for gastric cancer with severe peritoneal metastasis. Anticancer Res. 2017;37(12):7037–42.29187492, Masuishi T , Kadowaki S , Kondo M , et al. FOLFOX as first‐line therapy for gastric cancer with severe peritoneal metastasis. Anticancer Res. 2017;37(12):7037–42.29187492
F. Greene, D. Page, I. Fleming, J. Fritz, C. Balch, D. Haller (2002)
AJCC Cancer Staging Manual. 6th ed
Yoon-Koo Kang, W. Kang, D. Shin, J. Chen, J. Xiong, J. Wang, M. Lichinitser, Z. Guan, R. Khasanov, L. Zheng, M. Philco-Salas, T. Suarez, J. Santamaría, G. Forster, P. Mccloud (2009)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.Annals of oncology : official journal of the European Society for Medical Oncology, 20 4
( Ishigami S , Natsugoe S , Nakajo A , et al. Salvage gastrectomy following a combination of biweekly paclitaxel and S‐1 for stage IV gastric cancer. J Gastrointest Surg. 2008;12(8):1370–5.18516651)
Ishigami S , Natsugoe S , Nakajo A , et al. Salvage gastrectomy following a combination of biweekly paclitaxel and S‐1 for stage IV gastric cancer. J Gastrointest Surg. 2008;12(8):1370–5.18516651Ishigami S , Natsugoe S , Nakajo A , et al. Salvage gastrectomy following a combination of biweekly paclitaxel and S‐1 for stage IV gastric cancer. J Gastrointest Surg. 2008;12(8):1370–5.18516651, Ishigami S , Natsugoe S , Nakajo A , et al. Salvage gastrectomy following a combination of biweekly paclitaxel and S‐1 for stage IV gastric cancer. J Gastrointest Surg. 2008;12(8):1370–5.18516651
K. Yamaguchi, Kazuhiro Yoshida, Toshiyuki Tanahashi, Takao Takahashi, N. Matsuhashi, Yoshihiro Tanaka, K. Tanabe, H. Ohdan (2017)
The long-term survival of stage IV gastric cancer patients with conversion therapyGastric Cancer, 21
( Sobin LGM , Wittekind C . TNM classification of malignant tumours, 7th edn. Hoboken: Wiley‐Blackwell; 2009.)
Sobin LGM , Wittekind C . TNM classification of malignant tumours, 7th edn. Hoboken: Wiley‐Blackwell; 2009.Sobin LGM , Wittekind C . TNM classification of malignant tumours, 7th edn. Hoboken: Wiley‐Blackwell; 2009., Sobin LGM , Wittekind C . TNM classification of malignant tumours, 7th edn. Hoboken: Wiley‐Blackwell; 2009.
Kazuhiro Yoshida, M. Ninomiya, N. Takakura, N. Hirabayashi, W. Takiyama, Yuji Sato, S. Todo, M. Terashima, M. Gotoh, J. Sakamoto, M. Nishiyama (2006)
Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerClinical Cancer Research, 12
( Kinoshita T , Kinoshita T , Saiura A , Esaki M , Sakamoto H , Yamanaka T . Multicentre analysis of long‐term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. 2014;102(1):102–7.25389030)
Kinoshita T , Kinoshita T , Saiura A , Esaki M , Sakamoto H , Yamanaka T . Multicentre analysis of long‐term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. 2014;102(1):102–7.25389030Kinoshita T , Kinoshita T , Saiura A , Esaki M , Sakamoto H , Yamanaka T . Multicentre analysis of long‐term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. 2014;102(1):102–7.25389030, Kinoshita T , Kinoshita T , Saiura A , Esaki M , Sakamoto H , Yamanaka T . Multicentre analysis of long‐term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. 2014;102(1):102–7.25389030
T. Masuishi, S. Kadowaki, M. Kondo, A. Komori, K. Sugiyama, S. Mitani, K. Honda, Y. Narita, H. Taniguchi, T. Ura, M. Ando, H. Mishima, K. Muro (2017)
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.Anticancer research, 37 12
( Suzuki T , Tanabe K , Taomoto J , et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 2010;1(4):743–7.22966373)
Suzuki T , Tanabe K , Taomoto J , et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 2010;1(4):743–7.22966373Suzuki T , Tanabe K , Taomoto J , et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 2010;1(4):743–7.22966373, Suzuki T , Tanabe K , Taomoto J , et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 2010;1(4):743–7.22966373
( Bang YJ , Kim YW , Yang HK , et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomised controlled trial. Lancet. 2012;379(9813):315–21.22226517)
Bang YJ , Kim YW , Yang HK , et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomised controlled trial. Lancet. 2012;379(9813):315–21.22226517Bang YJ , Kim YW , Yang HK , et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomised controlled trial. Lancet. 2012;379(9813):315–21.22226517, Bang YJ , Kim YW , Yang HK , et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomised controlled trial. Lancet. 2012;379(9813):315–21.22226517
( National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) v4.0.)
National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) v4.0.National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) v4.0., National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Additional supporting information may be found in the online version of the article at the publisher's website. How to cite this article
Y. Bang, E. Cutsem, A. Feyereislova, H. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, Julie Hill, M. Lehle, J. Rüschoff, Yoon-Koo Kang (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 376
( Kanda T , Yajima K , Kosugi S , Ishikawa T , Ajioka Y , Hatakeyama K . Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S‐1‐based chemotherapy: a multi‐institute retrospective study. Gastric Cancer. 2011;15(3):235–44.22033890)
Kanda T , Yajima K , Kosugi S , Ishikawa T , Ajioka Y , Hatakeyama K . Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S‐1‐based chemotherapy: a multi‐institute retrospective study. Gastric Cancer. 2011;15(3):235–44.22033890Kanda T , Yajima K , Kosugi S , Ishikawa T , Ajioka Y , Hatakeyama K . Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S‐1‐based chemotherapy: a multi‐institute retrospective study. Gastric Cancer. 2011;15(3):235–44.22033890, Kanda T , Yajima K , Kosugi S , Ishikawa T , Ajioka Y , Hatakeyama K . Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S‐1‐based chemotherapy: a multi‐institute retrospective study. Gastric Cancer. 2011;15(3):235–44.22033890
A. Tsuburaya, J. Mizusawa, Y. Tanaka, N. Fukushima, A. Nashimoto, M. Sasako (2014)
Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasisBritish Journal of Surgery, 101
( Yoshida K , Kodera Y , Kochi M , et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC‐07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304.30925125)
Yoshida K , Kodera Y , Kochi M , et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC‐07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304.30925125Yoshida K , Kodera Y , Kochi M , et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC‐07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304.30925125, Yoshida K , Kodera Y , Kochi M , et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC‐07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296–304.30925125
AM Mandard, F Dalibard, JC Mandard (1994)
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma, 73
T. Kanda, K. Yajima, S. Kosugi, T. Ishikawa, Y. Ajioka, K. Hatakeyama (2012)
Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective studyGastric Cancer, 15
S. Ishigami, S. Natsugoe, Akihiro Nakajo, M. Matsumoto, Y. Uenosono, T. Arigami, T. Setoyama, Hideo Arima, Y. Uchikado, Y. Kita, K. Sasaki, T. Aikou (2008)
Salvage Gastrectomy Following a Combination of Biweekly Paclitaxel and S-1 for Stage IV Gastric CancerJournal of Gastrointestinal Surgery, 12
Kazuhiro Yoshida, K. Yamaguchi, N. Okumura, Toshiyuki Tanahashi, Y. Kodera (2015)
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classificationGastric Cancer, 19
Annals of Gastroenterological Surgery – Wiley
Published: Mar 1, 2022
Keywords: adjuvant surgery; chemotherapy; conversion therapy; gastric cancer; metastatic gastric cancer
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.